JNJ Stock Forecast & Price Target

Johnson & Johnson is underpinned by a diversified, high-quality growth engine in Innovative Medicine, where recent launches such as Icotyde, Inlexzo, Tecvayli and Talvey are building on blockbuster franchises like Tremfya, Darzalex and Cavykti, while management still sees room to lift sales estimates across multiple assets and expects long-term double-digit top-line growth. The company’s recent results reinforce that view, with 2Q 2026 sales of $25.3Bn and EPS of $2.90 both ahead of consensus, adjusted operational sales growth of 6.9% in Innovative Medicine and 3.7% in MedTech, and raised 2026 guidance to $100.8-101.4Bn of reported sales and $11.60-$11.75 of adjusted reported EPS. Even with near-term headwinds from Xarelto’s loss of exclusivity in 2027, newer product ramp-up, MedTech volatility in cardiovascular, and litigation and R&D investment needs, the breadth of 28 platforms each generating more than $1B in annual revenue, the expected margin tailwind as Darzalex royalties wind down in 2029 and beyond, and improving efficiency from supply chain and AI support a constructive fundamental outlook.

Johnson & Johnson is facing a challenging fundamental setup because, despite its scale and reach across 350MM patients annually, its growth depends heavily on a pipeline that still needs to prove itself through a concentrated set of 2026 and beyond catalysts in oncology, immunology, and neurology, including multiple Phase 3 readouts and regulatory milestones that remain uncertain. The company’s post-consumer structure has sharpened its focus on innovation and may improve productivity, but it also leaves valuation support more dependent on execution in the Pharmaceutical and MedTech segments, where roughly just over half of revenue comes from the United States and where any disappointment in major programs like MajesTEC-9, MonumenTAL-6, SunRISe-5, Icotyde, or Caplyta could pressure expected growth and margins. Although management emphasizes disciplined capital allocation, R&D investment, dividends, and selective M&A, the negative outlook reflects the reality that a highly regulated business with high-quality and safety demands must convert this capital into durable commercial wins before the promised uplift in revenue growth and earnings becomes convincing.